Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Bayer

< Previous 1 2 3 4 5 6 7 8 Next >
Updated Vitrakvi® (larotrectinib) Sub-Analysis at ATA 2021 Supports Efficacy and Safety in Adult and Pediatric TRK Fusion Thyroid Cancer Patients
From Bayer
Via Business Wire
Bayer Issues Voluntary Recall of Specific Lotrimin® and Tinactin® Spray Products Due to the Presence of Benzene
From Bayer
Via Business Wire
Midol® by Bayer Receives Honorable Mention in Fast Company’s 2021 Innovation by Design Awards
From Bayer
Via Business Wire
Bayer Hires Nicole Hayes as Director of U.S. External Communications
From Bayer
Via Business Wire
On the 15th Anniversary of World Contraception Day Bayer Releases Survey Results that Highlight the Role of Contraceptives in Women’s Lives
From Bayer
Via Business Wire
Bayer Extends Clinical Development Program for KERENDIA® (finerenone) With Phase III Study to Investigate Use in Patients With Nondiabetic Chronic Kidney Disease
From Bayer
Via Business Wire
Latest Analyses of Vitrakvi® (larotrectinib) Support Consistently Meaningful Clinical Profile for Both Adult and Pediatric Patients with TRK Fusion Cancer
From Bayer
Via Business Wire
NUBEQA® (darolutamide) Impact on Local Symptoms Evaluated in Men with Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC)
From Bayer
Via Business Wire
Andes Raises USD 15 Million in Series A Funding Co-Led by Leaps by Bayer and Cavallo Ventures
From Bayer
Via Business Wire
Tickers OTC
Bayer Announces Recipients of the Second Annual Pulmonary Hypertension Accelerated Awards
From Bayer
Via Business Wire
Bayer to Highlight Expanded Research from Growing Oncology Portfolio at ESMO Congress 2021
From Bayer
Via Business Wire
Bayer and Luke Bryan Team Up Again for “Here’s to the Farmer” Campaign
From Bayer
Via Business Wire
Bayer Starts Phase III Clinical Development Program OASIS With Investigational Product, Elinzanetant
From Bayer
Via Business Wire
Bayer Announces KERENDIA® (finerenone) Reduces the Risk of Cardiovascular Outcomes in New Phase III FIGARO-DKD Study in Adults With Chronic Kidney Disease (Stages 1-4) Associated With Type 2 Diabetes
From Bayer
Via Business Wire
FDA Label Updates Reflect Bayer’s Commitment to Women’s Healthcare
From Bayer
Via Business Wire
Bayer Announces Filing of Petition to U.S. Supreme Court for Review of Hardeman Decision
From Bayer
Via Business Wire
Bayer Strengthens Drug Discovery Platform Through Acquisition of Vividion Therapeutics
From Bayer
Via Business Wire
Bayer Provides Update on Path to Closure of Roundup™ Litigation
From Bayer
Via Business Wire
Denise Vitola Joins Bayer Communications Team
From Bayer
Via Business Wire
Bayer Once Again Earns Top Marks in 2021 Disability Equality Index
From Bayer
Via Business Wire
Bayer’s KERENDIA® (finerenone) Receives U.S. FDA Approval for Treatment of Patients with Chronic Kidney Disease Associated with Type 2 Diabetes
From Bayer
Via Business Wire
Bayer’s KERENDIA® (finerenone) Receives U.S. FDA Approval for Treatment of Patients with Chronic Kidney Disease Associated with Type 2 Diabetes
From Bayer
Via Business Wire
Bayer Submits Regulatory Applications for Oncology Treatment Investigational Combination of Aliqopa® (copanlisib) and rituximab in the U.S. and EU
From Bayer
Via Business Wire
FDA Approves Astepro® Allergy Nasal Spray for Over-the-Counter Use in the United States
From Bayer
Via Business Wire
ZERO – The End of Prostate Cancer and Bayer Band Together with Twisted Sister’s Jay Jay French to Raise Awareness about Prostate Cancer Screening and Treatment
From Bayer
Via Business Wire
Bayer Announces First ‘Precision Oncology Patient Innovation Awards’
From Bayer
Via Business Wire
Bayer to Advance Two First-of-its-Kind Investigational Cell and Gene Therapies for Parkinson’s Disease
From Bayer
Via Business Wire
Bayer Acquires Noria and PSMA Therapeutics to Expand Pipeline in Prostate Cancer
From Bayer
Via Business Wire
Bayer announces five-point plan to effectively address potential future Roundup™ claims
From Bayer
Via Business Wire
Long-term Data on Vitrakvi® (larotrectinib) Further Demonstrate Strong Clinical Profile in Patients with TRK Fusion Cancer Regardless of Tumor Type and Age
From Bayer
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.